AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Cambridge: AstraZeneca has announced that the company's supplemental Biologics License Application (sBLA) for Imfinzi ...

In this symposium, Frank Griesinger, Cecilia Pompili, and Jesme Fox discussed the latest evidence for neoadjuvant ...

With increased adoption of next-generation sequencing, tailored therapy on the basis of molecular status is being delivered for patients with early-stage resectable non–small-cell lung cancer (NSCLC).

CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial ...

A comparison of TPS 1-49% vs ≥50% showed a big improvement with the higher TPS for oleclumab-durvalumab (5.6% vs 32.0%) and smaller increases with monalizumab-durvalumab (30.0% vs 35.0%) and ...

NeoADAURA is a randomized global phase III study investigating the efficacy of neoadjuvant osimertinib-containing regimens in patients with resectable EGFR-mutated stage II to IIIB non–small-cell lung ...

Research Summary Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer DOI: 10.1056/NEJMdo007263 Save ...